New data shows that government-funded health insurance plans in the United States provide the majority of coverage for ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Wegovy's approval by China's NMPA targets individuals with a BMI of 30+ with related health issues; initial supply will be ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

Not only is Wegovy extremely effective (people lose about 15% of their body weight in a year), it also appears to have many ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...